1.A Phase II Study of Preoperative Chemoradiotherapy with Capecitabine Plus Simvastatin in Patients with Locally Advanced Rectal Cancer
Hyunji JO ; Seung Tae KIM ; Jeeyun LEE ; Se Hoon PARK ; Joon Oh PARK ; Young Suk PARK ; Ho Yeong LIM ; Jeong Il YU ; Hee Chul PARK ; Doo Ho CHOI ; Yoonah PARK ; Yong Beom CHO ; Jung Wook HUH ; Seong Hyeon YUN ; Hee Cheol KIM ; Woo Yong LEE ; Won Ki KANG
Cancer Research and Treatment 2023;55(1):189-195
Purpose:
The purpose of this phase II trial was to evaluate whether the addition of simvastatin, a synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, to preoperative chemoradiotherapy (CRT) with capecitabine confers a clinical benefit to patients with locally advanced rectal cancer (LARC).
Materials and Methods:
Patients with LARC (defined by clinical stage T3/4 and/or lymph node positivity) received preoperative radiation (45-50.4 Gy in 25-28 daily fractions) with concomitant capecitabine (825 mg/m2 twice per day) and simvastatin (80 mg, daily). Curative surgery was planned 4-8 weeks after completion of the CRT regimen. The primary endpoint was pathologic complete response (pCR). The secondary endpoints included sphincter-sparing surgery, R0 resection, disease-free survival, overall survival, the pattern of failure, and toxicity.
Results:
Between October 2014 and July 2017, 61 patients were enrolled; 53 patients completed CRT regimen and underwent total mesorectal excision. The pCR rate was 18.9% (n=10) by per-protocol analysis. Sphincter-sparing surgery was performed in 51 patients (96.2%). R0 resection was achieved in 51 patients (96.2%). One patient experienced grade 3 liver enzyme elevation. No patient experienced additional toxicity caused by simvastatin.
Conclusion
The combination of 80 mg simvastatin with CRT and capecitabine did not improve pCR in patients with LARC, although it did not increase toxicity.
2.Basic Therapeutic Approach for Patients with Plaque Psoriasis:Korean Expert Consensus Using the Modified Delphi Method
Seong Jin JO ; Yoo Sang BAEK ; Tae-Gyun KIM ; Ki-Heon JEONG ; Jeong Eun KIM ; Yu Sung CHOI ; Byungsoo KIM ; Eun-So LEE ; Yong Beom CHOE ;
Annals of Dermatology 2023;35(3):173-182
Background:
Currently, there is no consensus on the treatment of psoriasis in Korean patients.
Objective:
This study aimed to establish a consensus on the basic therapeutic principles for Korean patients with plaque psoriasis.
Methods:
Using the modified Delphi method, a steering committee proposed 53 statements for the first Delphi round, which covered five subjects: (1) the goal of treatment and evaluation of disease severity, (2) topical therapy, (3) phototherapy, (4) conventional systemic therapy, and (5) biologic therapy. The panel of dermatologists scored the level of agreement for each statement on a ten-point scale with scores ranging from 1 (strongly disagree) to 10 (strongly agree). After discussing the results of the first round, the committee reformulated 41 statements. Finally, consensus was defined as more than 70% of the second round scores being ≥7.
Results:
The panel participants strongly agreed that the ideal treatment goals for Korean patients with plaque psoriasis should include complete skin clearance and high dermatological quality of life. A strong consensus was also reached on the use of topical agents for psoriasis of any severity, the consideration of phototherapy before biologics therapy, the conventional systemic agents for moderate-to-severe psoriasis, and the recommendation of biologic for retractable psoriasis to conventional systemic therapy and phototherapy.
Conclusion
This modified Delphi panel established an expert consensus on the therapeutic approach for Korean patients with plaque psoriasis. This consensus may improve the treatment outcomes for psoriasis in Korea.
3.The Economic Burden of Psoriasis in Korea
Byeol HAN ; Ki-Heon JEONG ; Tae-Gyun KIM ; Kwang Joong KIM ; Dong Hyun KIM ; Byung-Soo KIM ; Kyung Duck PARK ; Chul Jong PARK ; Hai-Jin PARK ; Chul Hwan BANG ; Bong Seok SHIN ; Sang Woong YOUN ; Jai Il YOUN ; Ju Hee LEE ; Kyung Eun JUNG ; Yong Beom CHOE ; Seong-jin JO
Korean Journal of Dermatology 2021;59(5):321-331
Background:
Psoriasis is a chronic disease that can have accompanying comorbidities including arthritis, metabolic syndrome, and cardiovascular diseases. Patients with psoriasis tend to frequently visit medical institutions, and their economic burden for medical services is high.
Objective:
To investigate the economic burden of psoriasis in Korea.
Methods:
The Korean Society for Psoriasis conducted a multi-center field survey of the patients and analyzed the national insurance claim data. Also, we discussed the medical environment of psoriasis in Korea based on the results.
Results:
The economic burden of psoriasis patients is substantial and varied by the type of medical institute. Patients also paid the indirect and intangible medical costs. Biological agents, which is used in patients with severe psoriasis, led to an increase in the cost.
Conclusion
This is the first study to estimate the economic burden of psoriasis in Korea comprehensively. To improve the medical environment of psoriasis and alleviate the burden of patients, discussion on the more efficient health policy and medical insurance criteria for psoriasis would be needed.
4.The Economic Burden of Psoriasis in Korea
Byeol HAN ; Ki-Heon JEONG ; Tae-Gyun KIM ; Kwang Joong KIM ; Dong Hyun KIM ; Byung-Soo KIM ; Kyung Duck PARK ; Chul Jong PARK ; Hai-Jin PARK ; Chul Hwan BANG ; Bong Seok SHIN ; Sang Woong YOUN ; Jai Il YOUN ; Ju Hee LEE ; Kyung Eun JUNG ; Yong Beom CHOE ; Seong-jin JO
Korean Journal of Dermatology 2021;59(5):321-331
Background:
Psoriasis is a chronic disease that can have accompanying comorbidities including arthritis, metabolic syndrome, and cardiovascular diseases. Patients with psoriasis tend to frequently visit medical institutions, and their economic burden for medical services is high.
Objective:
To investigate the economic burden of psoriasis in Korea.
Methods:
The Korean Society for Psoriasis conducted a multi-center field survey of the patients and analyzed the national insurance claim data. Also, we discussed the medical environment of psoriasis in Korea based on the results.
Results:
The economic burden of psoriasis patients is substantial and varied by the type of medical institute. Patients also paid the indirect and intangible medical costs. Biological agents, which is used in patients with severe psoriasis, led to an increase in the cost.
Conclusion
This is the first study to estimate the economic burden of psoriasis in Korea comprehensively. To improve the medical environment of psoriasis and alleviate the burden of patients, discussion on the more efficient health policy and medical insurance criteria for psoriasis would be needed.
5.Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Ji Eun JUN ; In Kyung JEONG ; Jae Myung YU ; Sung Rae KIM ; In Kye LEE ; Kyung Ah HAN ; Sung Hee CHOI ; Soo Kyung KIM ; Hyeong Kyu PARK ; Ji Oh MOK ; Yong ho LEE ; Hyuk Sang KWON ; So Hun KIM ; Ho Cheol KANG ; Sang Ah LEE ; Chang Beom LEE ; Kyung Mook CHOI ; Sung Ho HER ; Won Yong SHIN ; Mi Seung SHIN ; Hyo Suk AHN ; Seung Ho KANG ; Jin Man CHO ; Sang Ho JO ; Tae Joon CHA ; Seok Yeon KIM ; Kyung Heon WON ; Dong Bin KIM ; Jae Hyuk LEE ; Moon Kyu LEE
Diabetes & Metabolism Journal 2020;44(1):78-90
BACKGROUND:
Cardiovascular risk remains increased despite optimal low density lipoprotein cholesterol (LDL-C) level induced by intensive statin therapy. Therefore, recent guidelines recommend non-high density lipoprotein cholesterol (non-HDL-C) as a secondary target for preventing cardiovascular events. The aim of this study was to assess the efficacy and tolerability of omega-3 fatty acids (OM3-FAs) in combination with atorvastatin compared to atorvastatin alone in patients with mixed dyslipidemia.
METHODS:
This randomized, double-blind, placebo-controlled, parallel-group, and phase III multicenter study included adults with fasting triglyceride (TG) levels ≥200 and <500 mg/dL and LDL-C levels <110 mg/dL. Eligible subjects were randomized to ATOMEGA (OM3-FAs 4,000 mg plus atorvastatin calcium 20 mg) or atorvastatin 20 mg plus placebo groups. The primary efficacy endpoints were the percent changes in TG and non-HDL-C levels from baseline at the end of treatment.
RESULTS:
After 8 weeks of treatment, the percent changes from baseline in TG (−29.8% vs. 3.6%, P<0.001) and non-HDL-C (−10.1% vs. 4.9%, P<0.001) levels were significantly greater in the ATOMEGA group (n=97) than in the atorvastatin group (n=103). Moreover, the proportion of total subjects reaching TG target of <200 mg/dL in the ATOMEGA group was significantly higher than that in the atorvastatin group (62.9% vs. 22.3%, P<0.001). The incidence of adverse events did not differ between the two groups.
CONCLUSION
The addition of OM3-FAs to atorvastatin improved TG and non-HDL-C levels to a significant extent compared to atorvastatin alone in subjects with residual hypertriglyceridemia.
6.The Impact of Androgen Receptor and Histone Deacetylase 1 Expression on the Prognosis of Ductal Carcinoma In Situ
Choong Man LEE ; Il Yong CHUNG ; Yangsoon PARK ; Keong Won YUN ; Hwi Gyeong JO ; Hye Jin PARK ; Hee Jin LEE ; Sae Byul LEE ; Hee Jeong KIM ; Beom Seok KO ; Jong Won LEE ; Byung Ho SON ; Sei Hyun AHN ; Jisun KIM
Journal of Breast Cancer 2020;23(6):610-621
Purpose:
Factors associated with invasive recurrence (REC) of ductal carcinoma in situ (DCIS) are less known. This study was aimed at identifying better biomarkers to predict the prognosis of DCIS.
Methods:
RNA extracted from formalin-fixed paraffin-embedded blocks of twenty-four pure DCIS cases was subjected to differential gene expression analysis. The DCIS cases were selected by matching age and estrogen receptor status. Sixteen REC-free and 8 invasive-REC cases with disease-free interval of > 5 years were analyzed. Immunohistochemistry (IHC) staining was used to validate sixty-one independent pure DCIS cases, including invasive-REC (n = 16) and REC-free (n = 45) cases.
Results:
Eight differentially expressed genes (DEGs) were statistically significant (log 2-fold change [FC] < –1 or > 1 and p < 0.001). Less than ½ fold expression of CUL1, androgen receptor (AR), RPS27A, CTNNB1, MAP3K1, PRKACA, GNG12, MGMT genes was observed in the REC group compared to the no evidence of disease group. AR and histone deacetylase 1 (HDAC1) genes were selected for external validation (AR: log 2-FC − 1.35, p < 0.001, and HDAC1: log 2-FC − 0.774, p < 0.001). External validation showed that the absence of AR and high HDAC1 expression were independent risk factors for invasive REC (hazard ratio [HR], 5.04; 95% confidence interval [CI], 1.24–20.4; p = 0.023 and HR, 3.07; 95% CI, 1.04–9.04; p = 0.042). High nuclear grade 3 was also associated with long-term invasive REC.
Conclusion
Comparative gene expression analysis of pure DCIS revealed 8 DEGs among recurring cases. External validation with IHC suggested that the absence of AR and overexpression of HDAC1 are associated with a greater risk of long-term invasive REC of pure DCIS.
7.Open Surgical Repair Using the Femoral Vein for a Mycotic Superior Mesenteric Artery Aneurysm.
Min NAMKOONG ; Seok Beom HONG ; Hwan Wook KIM ; Keon Hyon JO ; Jang Yong KIM
The Korean Journal of Thoracic and Cardiovascular Surgery 2018;51(3):209-212
Superior mesenteric artery (SMA) aneurysms are rare and often fatal. A 72-year-old man had previously been admitted to the emergency room with epigastric pain and heart murmur. The echocardiographic diagnosis was vegetation on the aortic and mitral valves, with moderate regurgitation from both valves due to infective endocarditis. No aneurysm was detected on abdominal computed tomography, and emergency double-valve replacement was performed. On postoperative day 25, the patient experienced abrupt abdominal pain, and computed tomography revealed a mycotic SMA aneurysm. Open surgical repair of the SMA aneurysm was performed using the femoral vein, and the patient's postoperative course was uneventful.
Abdominal Pain
;
Aged
;
Aneurysm*
;
Diagnosis
;
Echocardiography
;
Emergencies
;
Emergency Service, Hospital
;
Endocarditis
;
Femoral Vein*
;
Heart Murmurs
;
Humans
;
Mesenteric Artery, Superior*
;
Mitral Valve
;
Sternotomy
8.The Short-term Outcome and Safety of Laparoscopic Colorectal Cancer Resection in Very Elderly Patients.
Won Beom JUNG ; Jin Yong SHIN ; Byoung Jo SUH
The Korean Journal of Gastroenterology 2017;69(5):291-297
BACKGROUND/AIMS: Due to the recent increase in elderly population, laparoscopic surgery is more frequently performed in the elderly. This study aimed to compare the short-term outcomes of laparoscopic colorectal cancer surgery between the very elderly group (VEG), categorized as those with age over 80 years and the elderly group (EG), categorized as those with age 65 to 79 years. METHODS: We retrospectively compared 48 very elderly patients with 96 elderly patients (1:2 matched) who underwent laparoscopic resection for colorectal cancers at our institution between March 2010 and December 2014. The clinicopathologic parameters, surgical characteristics and short term outcomes were compared. RESULTS: There was no statistically significant difference in clinicopathologic characteristics between VEG and EG. Postoperative pain score (7 points vs. 6 points, p=0.264), time to first flatus (3 days vs. 3 days, p=0.335), hospital stay (15 days vs. 16.5 days, p=0.361), complication rates (47.9% vs. 26.0%, p=0.147) and major complication rate (25% vs. 20.8%, p=0.681) were not statistically different between the two groups. Before surgery, VEG had higher rate of neurologic underlying disease, such as dementia or cerebrovascular disease, than EG (25.0% vs. 7.3%, p=0.007). CONCLUSIONS: There was no significant difference in the clinicopathologic characteristics, short-term outcomes, and complication rates for laparoscopic colorectal resection between VEG and EG, except delirium. Age over 80 years may be relevant for the application of laparoscopic colorectal cancer resection.
Aged*
;
Cerebrovascular Disorders
;
Colorectal Neoplasms*
;
Delirium
;
Dementia
;
Flatulence
;
Humans
;
Laparoscopy
;
Length of Stay
;
Pain, Postoperative
;
Retrospective Studies
9.Korean Shock Society septic shock registry: a preliminary report.
Tae Gun SHIN ; Sung Yeon HWANG ; Gu Hyun KANG ; Won Young KIM ; Seung Mok RYOO ; Kyuseok KIM ; You Hwan JO ; Sung Phil CHUNG ; Young Seon JOO ; Jin Ho BEOM ; Sung Hyuk CHOI ; Young Hoon YOON ; Woon Yong KWON ; Tae Ho LIM ; Kap Su HAN ; Han Sung CHOI ; Gil Joon SUH
Clinical and Experimental Emergency Medicine 2017;4(3):146-153
OBJECTIVE: To evaluate the clinical characteristics, therapeutic interventions, and outcomes of patients with septic shock admitted to the emergency department (ED). METHODS: This study was a preliminary, descriptive analysis of a prospective, multi-center, observational registry of the EDs of 10 hospitals participating in the Korean Shock Society. Patients aged 19 years or older who had a suspected or confirmed infection and evidence of refractory hypotension or hypoperfusion were included. RESULTS: A total of 468 patients were enrolled (median age, 71.3 years; male, 55.1%; refractory hypotension, 82.9%; hyperlactatemia without hypotension, 17.1%). Respiratory infection was the most common source of infection (31.0%). The median Sepsis-related Organ Failure Assessment score was 7.5. The sepsis bundle compliance was 91.2% for lactate measurement, 70.3% for blood culture, 68.4% for antibiotic administration, 80.3% for fluid resuscitation, 97.8% for vasopressor application, 68.0% for central venous pressure measurement, 22.0% for central venous oxygen saturation measurement, and 59.2% for repeated lactate measurement. Among patients who underwent interventions for source control (n=117, 25.1%), 43 (36.8%) received interventions within 12 hours of ED arrival. The in-hospital, 28-day, and 90-day mortality rates were 22.9%, 21.8%, and 27.1%, respectively. The median ED and hospital lengths of stay were 6.8 hours and 12 days, respectively. CONCLUSION: This preliminary report revealed a mortality of over 20% in patients with septic shock, which suggests that there are areas for improvement in terms of the quality of initial resuscitation and outcomes of septic shock patients in the ED.
Central Venous Pressure
;
Compliance
;
Emergency Service, Hospital
;
Humans
;
Hyperlactatemia
;
Hypotension
;
Lactic Acid
;
Male
;
Mortality
;
Oxygen
;
Patient Care Bundles
;
Prospective Studies
;
Resuscitation
;
Sepsis
;
Shock*
;
Shock, Septic*
10.Retrospective Multicenter Study of Respiratory Syncytial Virus Prophylaxis in Korean Children with Congenital Heart Diseases.
Ah Young KIM ; Se Yong JUNG ; Jae Young CHOI ; Gi Beom KIM ; Young Hwue KIM ; Woo Sup SHIM ; I Seok KANG ; Jo Won JUNG
Korean Circulation Journal 2016;46(5):719-726
BACKGROUND AND OBJECTIVES: We conducted a review of current data on respiratory syncytial virus (RSV) prophylaxis with palivizumab, in Korean children with congenital heart diseases (CHD). In 2009, the Korean guideline for RSV prophylaxis had established up to five shots monthly per RSV season, only for children <1 year of age with hemodynamic significance CHD (HS-CHD). SUBJECTS AND METHODS: During the RSV seasons in 2009-2015, we performed a retrospective review of data for 466 infants with CHD, examined at six centers in Korea. RESULTS: Infants received an average of 3.7±1.9 (range, 1-10) injections during the RSV season. Fifty-seven HS-CHD patients (12.2%) were hospitalized with breakthrough RSV bronchiolitis, with a recurrence in three patients, one year after the initial check-up. Among patients with simple CHD, only five (1.1%) patients received one additional dose postoperatively, as per the limitations set by the Korean guideline. Among the 30 deaths (6.4%), five (1.1%) were attributed to RSV infection; three to simple CHD, one to Tetralogy of Fallot, and one to hypertrophic cardiomyopathy (HCM). Of the three HCM patients that exceeded guidelines for RSV prophylaxis, two (66.6%) were hospitalized, and one died of RSV infection (33.3%). CONCLUSION: In accordance to the Korean guideline, minimal injections of palivizumab were administered to patients having HS-CHD

Result Analysis
Print
Save
E-mail